RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families

[1]  Jian-Bing Fan,et al.  Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status , 2014, Scientific Reports.

[2]  A. Meindl,et al.  RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families , 2013, Breast Cancer Research.

[3]  Sheena M. Scroggins,et al.  Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.

[4]  R. Rouzier,et al.  Germline RAD51C mutations in ovarian cancer susceptibility , 2013, Clinical genetics.

[5]  R. Berger,et al.  Germline mutations in RAD51C in Jewish high cancer risk families , 2012, Breast Cancer Research and Treatment.

[6]  A. Meindl,et al.  Germline RAD51C mutations confer susceptibility to ovarian cancer , 2012, Nature Genetics.

[7]  F. Couch,et al.  Mutation screening of RAD51C in high-risk breast and ovarian cancer families , 2012, Familial Cancer.

[8]  J. Benítez,et al.  Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. , 2012, Human molecular genetics.

[9]  M. Blok,et al.  Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing , 2012, Breast Cancer Research and Treatment.

[10]  Samantha E. Boyle,et al.  Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients , 2012, Hereditary Cancer in Clinical Practice.

[11]  Y. Bignon,et al.  CHEK2 contribution to hereditary breast cancer in non-BRCA families , 2011, Breast Cancer Research.

[12]  Rochelle L. Garcia,et al.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[13]  Susan L. Neuhausen,et al.  RAD51C Germline Mutations in Breast and Ovarian Cancer Cases from High-Risk Families , 2011, PloS one.

[14]  J. Schleutker,et al.  RAD51C is a susceptibility gene for ovarian cancer. , 2011, Human molecular genetics.

[15]  A. Mannermaa,et al.  Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility , 2011, Breast Cancer Research and Treatment.

[16]  Yuntao Xie,et al.  RAD51C germline mutations in Chinese women with familial breast cancer , 2011, Breast Cancer Research and Treatment.

[17]  P. Pérez-Segura,et al.  A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families , 2011, Breast Cancer Research and Treatment.

[18]  R. Scott,et al.  BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer , 2011, Breast Cancer Research and Treatment.

[19]  D. Palli,et al.  Mutation screening of RAD51C in male breast cancer patients , 2011, Breast Cancer Research.

[20]  P. Sung,et al.  Enhancement of the RAD51 Recombinase Activity by the Tumor Suppressor PALB2 , 2010, Nature Structural &Molecular Biology.

[21]  Marc Tischkowitz,et al.  RAD51C germline mutations in breast and ovarian cancer patients , 2010, Breast Cancer Research.

[22]  Jing Zhang,et al.  Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer , 2010, Breast Cancer Research and Treatment.

[23]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[24]  Franca Fraternali,et al.  Mutation of the RAD51C gene in a Fanconi anemia–like disorder , 2010, Nature Genetics.

[25]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[26]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[27]  C Eng,et al.  Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome , 2004, Journal of Medical Genetics.

[28]  P. Oefner,et al.  Contributions of ATM mutations to familial breast and ovarian cancer. , 2003, Cancer research.

[29]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[30]  S C West,et al.  Identification and purification of two distinct complexes containing the five RAD51 paralogs. , 2001, Genes & development.

[31]  D. Schild,et al.  Mutants of the Five Rad51 Paralogs Recombinational Repair in Knockout Chromosome Instability and Defective , 2022 .

[32]  J. Fraumeni,et al.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[34]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[35]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[36]  M. Swift,et al.  Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.

[37]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .